A number of stocks fell in the afternoon session after a surprisingly hot wholesale inflation report fueled investor concerns ...

Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) will be reporting results this Tuesday before market hours ...

Q4 2025 Management View Olivier Loeillot, President and CEO, emphasized a strong finish to 2025 with revenue of $198 million for the fourth quarter and $738 million for the full year, translating to ...

As of Tuesday, February 24, Repligen Corporation’s RGEN share price has dipped by 6.43%, which has investors questioning if ...

Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) reported Q4 CY2025 results exceeding the market’s revenue expectations, with sales up 18.1% year on year to $197.9 million. The ...

Repligen (NASDAQ:RGEN) gains attention as Nasdaq Composite capital rotation reshapes biotech supplier valuations.

Repligen (RGEN) came out with quarterly earnings of $0.49 per share, beating the Zacks Consensus Estimate of $0.44 per share. This compares to earnings of $0.44 per share a year ago. These figures are ...

The company enters earnings with a forward price-to-earnings ratio of 81 times and a market capitalization of $7.64 billion. In its most recent quarter, Repligen beat expectations on both the top and ...

Conestoga Capital Advisors, an asset management company, released its fourth-quarter 2025 investor letter. As many believe, ...

Narrow-moat-rated Repligen is a leading provider of bioprocessing solutions for companies that manufacture biologic drugs. Its business lines include advanced filtration and fluid management systems ...

Fourth quarter revenue of $198 million, a year-over-year increase of 18% as reported, 14% organic with continued momentum in orders in the quarterFull year 2025 revenue of $738 million, a year-over-ye ...

On Tuesday, Repligen Corporation (NASDAQ:RGEN) reported fourth quarter results that exceeded analyst expectations. The company’s shares dipped 0.72% in pre-mark ...